Antengene Corp. Ltd. has outlined progress in its early-stage pipeline. The company has leveraged its Antengager T-cell engager (TCE) platform for the discovery of multiple investigational programs.
Mindrank Therapeutics (Suzhou) New Drug Research & Development Co. Ltd. has divulged molecular glue degraders comprising cereblon (CRBN) ligands acting as dual eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1) and casein kinase 1 isoform α (CSNK1A1) degradation inducers. They are reported to be potentially useful for the treatment of cancer, Alzheimer’s disease, inflammatory disorders, autoimmune diseases and metabolic diseases.
Anticancer drugs that work simultaneously through multiple mechanisms are sought after because of their potential for greater efficacy and robustness to resistance. Researchers at Capital Medical University and Chinese Institutes for Medical Research generated 21 ternary hybrids containing phenylsulfonylfuroxan, b-carboline und hydroxamic acid moieties.
Although tricomplex pan-RAS (ON) inhibitors, such as RMC-6236, constitute a promising class of therapeutics against RAS-driven cancers, their on-target, off-tumor toxicities challenge the dosing strategy and the safety of drug combinations.
Captain T Cell GmbH has successfully closed an equity financing round to support its T-cell receptor (TCR) T-cell therapies for solid tumors. The company’s autologous lead program, CTC-127, is a best-in-class TCR T-cell therapy targeting MAGE-A4-positive solid tumors and is expected to enter clinical trials in early 2027.
The inhibition of PD-L1 and VEGF individually or in combination has shown efficacy across several solid tumor types, but not all patients respond to therapy or respond for short duration. IMM-2510 is a novel bispecific antibody developed by Immuneonco Biopharmaceuticals Inc. that targets both PD-L1 and VEGF, thus achieving both angiogenesis inhibition and immune checkpoint blockade.
Researchers from Tango Therapeutics Inc. presented preclinical efficacy data on TNG-260, an inhibitor of the co-repressor of repressor element-1 silencing transcription (CoREST) deacetylase complex, designed to treat immunotherapy-resistant STK11-mutant tumors.
CIS Biopharma AG recently presented an antibody-drug conjugate (ADC) targeting the L1 cell adhesion molecule (L1CAM/CD171) as a potential candidate for the treatment of advanced tumors.
Sutro Biopharma Inc. has outlined its next-generation antibody-drug conjugate (ADC) pipeline following recent IND clearance and initiation of phase I for its tissue factor-targeting ADC, STRO-004.
